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CANCER IN YOUNG PEOPLE IN EUROPE
Every year in Europe 15,000 children aged 0–14 years and
20,000 teenagers and young adults aged 15–24 years are diagnosed
with cancer [1]. Overall survival at 5 years continuously improved
from 76.1% in 1999–2001 to 79.1% in 2005–2007 [2]. However,
6,000 young people in Europe still die of cancer each year despite
best available treatments. No progress has been made for
malignancies with the worst prognosis (brain tumours, neuroblas-
toma, sarcomas and acutemyeloid leukaemia). Across Europe there
are still major disparities in 5-year survival, for example Eastern
Europe reports 10–20% lower survival rates [2]. Cancer remains the
commonest disease causing death beyond the age of 1 year in
Europe. It is estimated that 300,000–500,000 European citizens are
In Europe, 6,000 young people die of cancer yearly, the
commonest disease causing death beyond the age of 1 year. In
addition, 300,000–500,000 European citizens are survivors of a
childhood cancer and up to 30% of them have severe long-term
sequelae of their treatment. Increasing both cure and quality of cure
are the two goals of the European paediatric haematology/oncology
community. SIOPE coordinates and facilitates research, care and
trainingwhich are implemented by the 18 European study groups and
23 national paediatric haematology/oncology societies. SIOPE is the
European branch of the International Society of Paediatric Oncology
and one of the six founding members of the European Cancer
Organisation. SIOPE is preparing its strategic agenda to assure long-
term sustainability of clinical and translational research in paediatric
malignancies over the next 15 years. SIOPE tackles the issues of equal
access to standard care and research across Europe and improvement
of long term follow up. SIOPE defined a comprehensive syllabus for
training European specialists. A strong partnership with parent,
patient and survivor organisations is being developed to successfully
achieve the goals of this patient-centred agenda. SIOPE is advocating
in the field of EU policies, such as the Clinical Trials Regulation and
the Paediatric Medicine Regulation, to warrant that the voice of
young people is heard and their needs adequately addressed. SIOPE
and the European community are entirely committed to the global
agenda against childhood cancers to overcome the challenges to
increasing both cure and quality of cure of young peoplewith cancer.
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survivors of a childhood cancer: 60% of them have at least one
chronic health problem and 30% have severe long-term sequel-
ae [3]. Increasing both cure rate and quality-of-cure (defined
by presence and intensity of treatment complications in a long-
term survivor) for young people with cancer are the two goals
for the next decade. The types of cancer occurring in this age
group in Europe are similar to those observed in the rest of the
world [4].
SIOP-EUROPE, THE PAN-EUROPEAN SOCIETY FOR
PAEDIATRIC HAEMATOLOGY/ONCOLOGY
SIOPE is the European branch of the International Society
of Paediatric Oncology (SIOP), and participates actively in the
global agenda, fighting childhood cancer [5]. SIOPE is also one of
the six founding members of the European CanCer Organisation
(ECCO) and thus participates actively in the European multi-
disciplinary oncology agenda with cancer societies of medical
oncologists, radiation oncologists, surgical oncologists, oncology
nurses and scientists as well as with the broader parents and
patients advocate community [6]. The clinical challenges of rare
conditions are shared by all children with cancer as well as many
adult patients with rare variants, now increasingly determined by
molecular sub-typing as part of the personalised medicine
agenda [7]. The recently emerged focus upon teenagers and young
adults (TYA) at the interface between paediatric and adult medicine
is a fruitful area for research collaboration and shared clinical
service development [8]. SIOPE will further develop collaboration
with the European Society of Medical oncology to better tackle the
TYA issues. It is hoped that improvements in both survival and
quality-of-survival will come from dedicated multi-professional
teams, with experts from paediatric and adult cancer backgrounds
collaborating. SIOPE sees itself as an important stakeholder in both
the Global Paediatric Oncology and the European Oncology
agendas.
SIOPE coordinates and facilitates European activities in
research, care and training. There are 23 National Paediatric
Haematology Oncology Societies or groups (NAPHOS; Fig. 1;
Table I) and 18 European study groups (Table II) running the
European research and care agenda in more than 60 different
paediatric malignancies and cross-cutting areas such as early drug
development, extremely rare cancers, teenagers and young adults
and long-term follow-up. Representatives from both NAPHOS and
from European Study Groups have joined together to form the
SIOPE European Clinical Research Council (ECRC). The ECRC
represents the common, harmonised voice for advocacy and
lobbying at the European level on paediatric and adolescent cancer
clinical and research activities.
Fig. 1. Map of paediatric haematology oncology in Europe. The figure shows member states from the European Union (blue) and out of the
European Union (pink), as well as member states with (plain colour) or without (dashed) a National Paediatric Haematology Oncology Society.
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During the last 10 years, SIOPE has increasingly represented
the voice of all those involved in paediatric and TYA cancer
at the EU political level. Proactive in its approach, the SIOPE
Office in Brussels with the SIOPE Board ensures that our
community’s concerns are heard and we strongly advocate
for them to be taken into account in EU policies, regulations
and legal initiatives. There is still the need for policy makers
and regulators to act on our proposals and new policies are
required to address adequately the global burden of childhood
cancers [9].
TABLE I. National Paediatric Haematology Oncology Societies or Groups (NAPHOS) in Europe
Country Name Acronym
Austria Austrian Group for Paediatric Haemato-Oncology AGPHO
Belgium Belgian Society of Paediatric Haematology Oncology BSPHO
Czech Republic Czech Working Group for Paediatric Oncology CPH
Denmark, Finland, Iceland, Norway, Sweden Nordic Society of Paediatric Haematology & Oncology NOPHO
Estonia Baltic Society of Paediatric Haemato-Oncology: Estonia BSPHO
France Socie´te´ Franc¸aise de lutte contre les Cancers et leuce´mies
de l’Enfant et l’adolescent
SFCE
Germany Gesellschaft fu¨r Pa¨diatrische Onkologie und Ha¨matologie GPOH
Greece Hellenic Society of Paediatric Haematology-Oncology
Hungary Hungarian Paediatric Oncology Network HPOG
Italy Associazione Italiana Ematologia Oncologia Pediatrica AIEOP
Latvia Latvian Society of Paediatric Oncology
Lithuania Lithuanian Society of Paediatric Oncology and Haematology LVOHD
Netherlands Stichting Kinderoncologie Nederland SKION
Poland Polish Society of Paediatric Oncology and Haematology
Portugal Sociedade de Hematologia e Oncologia Pediatrica SHOP
Romania Romanian Society of Paediatric Haematology/Oncology
Serbia Serbian Society of Haematology and Oncology
Slovak Republic Slovak Paediatric Association-Section of Paediatric Haemato-Oncology
Slovenia Slovenian Society of Paediatric Haematology and Oncology
Spain Sociedad Espa~nola de Hematologı´a y Oncologı´a Pedia´tricas SEHOP
Switzerland Schweizerischen Pa¨diatrischen Onkologie Gruppe SPOG
Turkey Turkish Paediatric Oncology Group TPOG
United Kingdom and Ireland Children’s Cancer Leukaemia Group CCLG
TABLE II. European and Europe-Centred International Study Groups in Paediatric Haematology/Oncology
Acronym Name Area Website
CWS Cooperative Weichteilsarkom Studiengruppe or
Cooperative Soft Tissue Sarcoma Study Group
Soft tissue sarcomas
EBMT-PDWP European Group for bone marrow and stem cell
transplantation: Paediatric Diseases Working Party
Transplantation www.ebmt.org
EHL European Hodgkin Consortium Hodgkin
EICNHL European Inter-group cooperation on childhood and
adolescent Non Hodgkin Lymphoma
Non-Hodgkin Lymphoma
EpSSG European Paediatric Soft Tissue Sarcoma Study Group Soft tissue sarcomas www.epssg.cineca.org
EURAMOS European and American Osteosarcoma Study Group Osteosarcoma www.euramos.org
EURO-EWING European Inter-group cooperation on Ewing tumours Ewing tumours
EWOG-MDS European Working Group of myelodysplasic syndrom and
juvenile myelomonocytic leukaemia in Childhood
Myelodysplasia www.ewog-mds.org
EXPeRT European Cooperative Study group on Paediatric Rare
Tumours
Extremely Rare cancers
GCT-group Germ Cell Tumours Germ cell tumours
Histiocyte Society Histiocyte Society Histocytosis www.histiocytesociety.org
I-BFM International BFM Study Group Leukaemia’s www.bfm-international.org
ITCC European Consortium for Innovative Therapies for
Children with Cancer
Early drug trials www.itcc-consortium.org
PanCare Pan-European Network for Care of Survivors after
Childhood and Adolescent Cancer
Long-term follow-up
and Survivorship issues
www.pancare.eu
SIOP RTSG SIOPE Wilms Tumour Study Group Wilms tumour www.siop-rtsg.eu
SIOPE-Brain SIOPE Brain tumour group Brain tumours
SIOPEL SIOPE Childhood Liver Tumours Strategy Group Liver tumours www.siopel.org
SIOPEN SIOPE Neuroblastoma Group Neuroblastoma www.siopen-r-net.org
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ASSURING LONG-TERM SUSTAINABILITY OF
CLINICAL AND TRANSLATIONAL RESEARCH IN
PAEDIATRIC MALIGNANCIES IN EUROPE
In 2008, SIOPE in collaboration with the European Study
Groups identified pitfalls and hurdles associated with running
clinical and translational research in order to define a strategy for
the next decades. Despite a long history of networking that
generated successful advances in cure rate, clinical research was
still fragmented in Europe and most groups and institutions faced
major difficulties to run investigator-driven clinical trials under the
EU Clinical Trials Directive. There was limited access to new
oncology drugs developed by pharmaceutical companies, despite
the introduction of the 2007 EU Paediatric Medicines Regulation.
The EU has funded several translational research projects in
paediatric cancers such as the KidsCancerKinome and European
Embyronal Tumour (EET)-pipeline projects but more needed to be
done. Integration between biology and clinical research remains
inadequate, at a time when personalised cancer medicine is
emerging. There is such a great disparity in access to the best
standard of care or trials of new therapies within research-based
care across Europe that impacts on survival outcomes for the
children [2]. Collaboration with parent organisations and survivors
needs to be strengthened and a lack of sustained and sufficient
funding in the context of the global economic crisis will further
jeopardise delivery of the research agenda.
The EU recognised the need for a “virtual institute” for
childhood and adolescent cancer. In 2011, the EU offered SIOPE
and 32 associated institutions and organisations the opportunity to
create the EU-funded European Network for Cancer research in
Children and Adolescents (ENCCA) [10]. This 4-year network of
excellence aims to structure a sustainable clinical and translational
research agenda in Europe over the next 15 years and build the
necessary tools and platforms to achieve further improvements in
both cure rate and quality-of-cure (Table III). Just over 2 years into
the program, ENCCA is progressing efficiently and is preparing the
long-term sustainable project for paediatric haematology/oncology
in Europe.
European Research is funded on a per project basis through
national and European grants as well as charities. Industry funds
less than 5% of projects. For the first time ever, funding was made
available through ENCCA (12 M s for 4 years) to structure clinical
and translational research in Europe. One of the key challenges for
long‐term sustainability will be to secure this structure funding for
TABLE III. The 10 Goals and Output of the European Network for Cancer Research in Children and Adolescents (ENCCA)
Goal Output
1 Create a sustainable “European Virtual Institute” for clinical and
translational research in childhood and adolescent cancers
Run the global European strategic plan
Facilitation of the implementation of investigator-driven clinical
trials
Rapid translation of new knowledge into patient care
2 Define the European Strategy to increase both cure and quality of
cure at the Horizon 2020
The seven medical and scientific objectives and road-map till 2020
The means and needs to run this strategic plan
3 Integrate all relevant stakeholders and enhance collaboration Ways to commit all stakeholders (clinicians, health professionals,
biologists, researchers, imaging developers, epidemiologists,
statisticians, drug developers, IT partners, parents and patients,
industry, ethical and regulatory authorities)
4 Reduce knowledge fragmentation and improve communication Strengthened integration of leukaemia and tumour groups
Increased critical mass of expertise and capacity to speed up clinical
research integrated into care
5 Improve therapeutic strategies by enabling better access to
innovative therapies, knowledge sharing and innovative
technology,
A biology-based therapeutic strategy for each paediatric malignancy
Shared and mutualised clinico-biological databases
Prioritisation of new drug development within the European
Paediatric Medicine Regulation
6 Improve the quality of life of children and adolescents with cancer
with particular emphasis on long term treatments side effects
A “Survivorship passport” available for each patient cured of a
paediatric malignancy
Facilitation of adequate risk-based advice, follow-up and care
7 Improve access to care and research for teenagers and young
adults (TYA)
Sharing practice and promoting service development,
interdisciplinary support and specific guidance for care of TYA
Strengthened collaboration with adult oncology
Creation of European TYA Steering groups with all stakeholders
and leading health professionals
8 Promote Innovative methodologies and designs for clinical trials Further address the rarity of patients and conditions to speed up the
evaluation of new drugs and new biomarker-driven therapeutic
strategies
9 Organize a comprehensive education and training programme For health professionals (clinicians, nurses and all professionals in
multidisciplinary teams), to facilitate the implementation of
standards of care across Europe as well as clinical research
For parents and patients, to increase their awareness on clinical
research
10 Propose common ethical definitions and adequate monitoring of
ethical issues
Identified, documented and classified ethical issues encountered in
paediatric oncology research
Guidelines
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integration, coordination and implementation of the research EU
agenda in paediatric haematology/oncology.
SIOPE is linking with other appropriate pan-European
initiatives such as the European Partnership for Actions Against
Cancer (EPAAC) for cancer outcomes research and advocacy [11],
and the EUROCANPLATFORM network for translational research
and precision medicine [12].
EQUAL ACCESS TO STANDARD OF CARE AND
RESEARCH ACROSS EUROPE
Equal access to the best standard of care across Europe is amajor
goal for SIOPE. Acknowledging that health is dealt with at the
national level (a Member State competency) and is not a European
prerogative, SIOPE and the International Confederation of
Childhood Cancer Parent Organisations (ICCCPO), considered
that guidelines outlining the minimum requirements for delivery of
standard of care would be a useful advocacy tool. Such guidelines
could help health professionals and parents’ and patients’ groups to
address inequalities by convincing their national health authorities
to optimise their efforts to reach and exceed 80% overall cure rates.
Through EPAAC [11], SIOPE worked with all health professionals,
including paediatric oncologists, nurses, physiotherapists and
psycho-social care workers as well as patient advocates, to design
and validate the European standards of care for Children
with cancer which are now available on the SIOPE website in 16
languages [13].
Treating children with cancer is complex and needs a
multidisciplinary specialised team. The European hub-and-spoke
model is already being set up in several countries, such as theUnited
Kingdom and France. In this model, a limited number of specialist
centres (the hubs) are responsible for accurate diagnosis, risk-
stratified treatment decision and complex treatments [3]. They liaise
with local centres (the spokes) to share the patient care, providing
less complex treatments such as simple chemotherapy and
components of supportive care along with careful monitoring
closer to patient’s home. A limited number of hub centres are also
resourced to deliver even more specialised treatments requiring
expert teams in for example: complex surgery, high precision
radiation therapy in vulnerable locations, high-dose chemotherapy
with haematopoietic stem cell support, access to innovative drugs in
early phase trials, MIBG therapy for high-risk neuroblastoma and
treatment for extremely rare cancers.
The number of centres with this higher level of expertise in
Europe is limited and referral of patients to these centres in other
regions and Member States needs to be coordinated. To support
patient treatment across borders, the EU Cross-Border Healthcare
Directive, a new EU Directive outlining patients’ rights to access
treatment abroad, was implemented in 2011. The European
Commission recently issued a call for the creation of a network
of reference centres in paediatric haematology/oncology to which
SIOPE responded. Based upon ongoing EU funded projects such as
ENCCA [10], PanCareSurFup [14] and INTREALL [15], SIOPE
along with 42 institutions and organisations proposed to build a
reference network named ExPO-r-Net for expert centres in
Paediatric Oncology which will integrate the SIOPE’s European
Standard of Care initiative. The proposal has been selected and
funded for 3 years (Table IV) and will be launched in 2014.
Paediatric oncology nurses are essential members of the
multidisciplinary teams taking care of children and adolescents.
They provide high quality, safe and effective nursing care which
is paramount to warrant access to standard treatments and
the best quality of life possible. There is a need to facilitate the
implementation of nursing research projects addressing, for
example and not limited to, symptoms management and quality
of life of patients and their families during treatment [16]. There is a
need to increase the role of nurses in clinical research which is
integrated into care and SIOPE will develop further the collabora-
tion with European paediatric oncology nurses.
Most paediatric malignancies develop rather rapidly as
compared to adult malignancies. Early diagnosis through large
national programmes is thus difficult to achieve with the exception
of the small minority of children and adolescents recognized to be at
increased genetic risk of developing a cancer. This is in contrast to
adult cancer screening programmes in breast, cervical and colo-
rectal cancers. For some patients, there is a long delay between the
first symptoms and diagnosis of cancer that delays initiation of
treatment and may jeopardise patient outcome. This may be disease
related [17]. Headsmart is a pilot project currently running in the
UK to reduce delays in diagnosis of brain tumours [18]. This is a
national public health campaign to raise awareness of the early
features of brain tumours among the public, schools and primary
care practitioners and the need for timely imaging.
TABLE IV. The Goals and Output of the ExPO-r-Net Project (European Expert Paediatric Oncology Reference Network for Diagnostics
and Treatment)
Goal Output/field
1 Identify the medical needs of rare children and adolescents with cancer with experts of the European
Council of Clinical Research and address the challenges in terms of costs, resources, psychological
burden and ethical aspects
Paediatric needs
2 Build a Paediatric Oncology European Research Network (ERN)—a roadmap to identified and certified
reference expert centres
Network
3 Establish a Paediatric Oncology tumour board ERN working to common standards and using IT tools based
on E-Health concepts for sharing and providing expertise and advice
Tumour boards
4 Define the criteria for a common process for identification and designation of paediatric oncology expert
centres in Europe
Criteria for designation
5 Address the cross-border dimension of long-term follow-up of childhood cancer survivors in Europe: the
survivorship passport as an instrument for crucial treatment and follow-up data
Long-term follow-up
6 Integrate very rare tumours and soft tissue sarcomas into the European reference network Very rare tumours
Pediatr Blood Cancer DOI 10.1002/pbc
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IMPROVING LONG-TERM FOLLOW-UP
With a 80% cure rate, the number of survivors, presently
estimated to be 300,000–500,000 in Europe, is likely to continue to
increase and improving their quality-of-life is a major goal [19].
To address this, the PanCare network was created in 2008 [14].
PanCare is a pan-European multidisciplinary network of health
professionals, survivors of a paediatric malignancy and their
families, collaborating to reduce the frequency, severity and impact
of late side-effects of treatments, with the aim to ensure that every
survivor of childhood cancer receives an optimal long-term care.
PanCare increases awareness and facilitates research about
childhood cancer survivors, as well as working towards promoting
health organisations to address the issues of long-term follow-up.
From within PanCare, 16 institutions from 11 European countries
formed the PanCareSurFup consortium which was selected and
fundedwithin the Seventh Framework Programme, at the same time
as ENCCA. PanCareSurFup carries out research on late effects such
as the effects of radiation therapy, cardiac toxicity and secondary
malignancies. Guidelines for follow-up, models of care and
transition are being established as well as the training needs of
health professionals. A Survivorship passport is being developed in
ENCCA in collaboration with PanCareSurFup aiming to provide
each cured child and adolescent with information on treatment
received and the relevant follow-up, including precautionary
measures to improve their quality-of-life despite the potentially
toxic treatment they received. The hope is to empower survivors to
take the responsibility for their own follow-up ensuring that they are
well-informed on what to be aware of, how and when to access care
and follow-up and who to turn to when and if they need and desire.
In 2014, PanCareLIFE, another PanCare-based 5-year EU-project,
will commence. PanCareLIFEwill focus on fertility and ototoxicity
issues as well as quality-of life after childhood cancer.
TRAINING MULTIDISCIPLINARY TEAMS
The quality of standard care delivered to children and
adolescents with cancer relies on well-trained multidisciplinary
teams. There are several European training and education
programmes such as those delivered by the European School of
Oncology, the Amsterdam School of Paediatric Oncology, the
Innovative Therapies for Children with Cancer and the Diplome
Inter-Universitaire d’Oncologie Pe´diatrique. In addition, SIOPE
supports the annual Flims Workshop on methods in clinical cancer
research. This highly competitive educational programme intro-
duces junior clinical oncologists in any oncology subspecialty to the
principles of good clinical trial design.
SIOPE prepared a comprehensive new syllabus in paediatric
haematology/oncology in collaboration with the European Acade-
mia of Paediatrics [20]. The goal is to ensure a standard training
programme throughout Europe, allowing specialists to be qualified
in paediatric haematology/oncology to exercise their skills in a
specialised tertiary care unit. The Syllabus sets out the minimum
requirements for a Europe-wide 2-year training programme. It is
designed in a modular fashion, covering haematological malignan-
cies and solid tumours, diagnostic, therapeutic approaches, research
methodologies and ethical issues as well as expertise in practical
procedures.
SIOPE has also developed in partnership with ECCO, three
educational videos providing accredited online educational
resources for young oncologists who need practice-oriented
training. The videos explain the standard procedures in paediatric
haematology/oncology such as lumbar puncture, bone marrow
aspiration and bone marrow biopsy.
PARTNERING WITH PARENT, PATIENT AND
SURVIVOR ORGANISATIONS
Building a partnership with parents, patients and survivors
organisations is essential to achieve the goals in terms of research,
equal access to standard care and expertise, advocacy when new
policies are developed and strategic decisions regarding priorities to
be undertaken at the national and European levels. SIOPE has been
working with ICCCPO for several years and ICCCPO is involved as
a partner in several European projects and initiatives.
ICCCPO is a worldwide childhood cancer organization
representing families of children with cancer and childhood cancer
survivor groups [21]. In addition, paediatric cancer survivors are
starting to create organisations, such as “Les Aguerris” [22] in
France, SurvivorNet [23] in the UK and UngCancer [24] in Sweden
and to build European networks. In 2011, ICCCPO European
members and survivors created the Parent and Patient Advocacy
Committee (PPAC) within ENCCA. Since that time they have
actively engaged in facilitating the networking between parent and
survivor groups and organisations, building a strong network of
survivor groups and disseminating health policy related issues
within Europe. The priorities are (i) closing the gap’ in research,
treatment and care between Western and Eastern Europe, (ii) the
training of parent and patient representatives in clinical research to
make them powerful advocates and partners in this field, (iii)
survivors’ issues and long-term follow-up (including the survivor-
ship passport), (iv) contribution to the definition and implementa-
tion of strategic objectives within Europe for the next 15 years.
ADVOCATING NEW EUROPEAN ONCOPOLICY
INITIATIVES
The EU Clinical Trials Directive (CTD) has significantly
impaired the capacity to run academic clinical trials due to the
substantially increased administrative burden and costs. As a
Directive, the CTD has been implemented differently by Member
States, generating substantial differences of interpretation, process
and priority across Europe, severely complicating the tasks for
academic sponsors running multinational clinical trials. Such trials
are essential for paediatric haematology/oncology, given the rarity
of childhood cancers. Consequently the number of clinical trials
recruiting patients to test new treatments has decreased significantly
in Europe [25]. Instead of revising the CTD, the European
Commission proposed a new legislation in the form of a Regulation
whichwill apply on the same day, in each EUMember Statewithout
any transposition [26]. SIOPE applauded this decision and worked
closely with the European Commission, the European Parliament
and the European Council to try and influence the content of the
Regulation so that it meets the needs of those running trials for
young people with rare cancers [27]. The critical points which have
been selected and strongly endorsed by SIOPE to ensure that the
new Regulation will be an improvement include: (i) the need for
simplified administrative process and reporting for clinical trials
with limited additional risk compared to normal clinical practice,
categorizing the risk linked to research rather than the current “one
Pediatr Blood Cancer DOI 10.1002/pbc
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size fits all” approach, (ii) the need for national indemnity schemes
to avoid the current situation where disproportionately high
insurance fees need to be raised by academia to cover investigator
driven academic clinical trials.
The European Paediatric Medicines Regulation that was
launched in 2007 to provide better medicines for children is a
highly relevant legislation for paediatric haematology/oncolo-
gy [28]. This Regulation is based on rewards, incentives and
obligations for pharmaceutical companies to develop drugs for
young people. There were high expectations that this legislation
would bring hope to children suffering with cancer with the
possibility that anticancer drugs for adults could also be developed
for children [29]. After 5 years, there has been a significant change
in the landscape of paediatric haematology/oncology drug
development in Europe and several new anticancer drugs are under
investigation. However, there is still an insufficient access to new
drugs. SIOPE along with ITCC and parent organisations have
voiced their concerns on limitations of the implementation of the
Paediatric Regulation in oncology during the Public Consultation
process on the 5-year interim report, prepared by the European
Medicines Agency in 2012. We supported proposals by the
EMA [30] and asked for a revocation of the class waiver list, the
approval of PIPs on the basis of the drugmechanism of action rather
than the adult indication along with a better prioritisation of drug
development, in order to make the Regulation successful in
addressing the urgent need for new safe and effective drugs
in paediatric haematology/oncology [31]. We will continue to
advocate for better incentives and regulation to cover the specific
needs of children and adolescents with cancer. This will become a
very important activity for SIOPE in the coming years.
In 2014, the EU launched Horizon 2020, the next EU framework
program for research and innovation, with three objectives:
excellence in science, competitive industries and tackling societal
challenges. SIOPE will make all efforts to assure that needs of
young people with cancer are adequately addressed.
BEING PART OF THE GLOBAL AGENDA AGAINST
CHILDHOOD CANCERS
Several European-centred study groups are international in their
scope and bring together global investigators to participate in a
common clinical trials portfolio. The IBFM-study group is
international and patients from countries outside Europe, such
as Argentina or Japan, participate to the IBFM leukaemia trials
and translational research projects [32]. Today, more than 100
institutions from Europe, Asia, Central and South America,
Australia and New Zealand collaborate in SIOPEL, the SIOPE-
Liver study group. Early drug trial groups such as ITCC in Europe,
POETIC and TACLE in North America, the Canadian C17 network
and the Australia Children’s Cancer Trials group are working
together to speed up the development of new anticancer agents [33].
SIOPEN built with the Children’s Oncology Group and neuro-
blatoma groups from Japan, China and Australia a large clinical and
biological database of more than 9,000 neuroblastoma patients in
order to define and validate new staging system, new biological
prognostic biomarkers through the International Neuroblastoma
Research Group [34]. Groups such as the SIOP-Renal Tumours
Study Group support clinical trials groups in other continents to run
studies using the same standard treatment backbones, adapted to
local circumstances [35].
CONCLUSION
Cancer in young people remains an important global public
health issue. Only cooperation between the European paediatric
haematology/oncology community of health professionals, re-
searchers, parents, patients and survivors together with all stake-
holders (national and European political bodies, regulatory
agencies, pharmaceutical companies, fund raising charities) and
including international collaborations will overcome the challenges
to increase both cure and quality of cure of children and adolescents
with cancer and to warrant long term sustainability.
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